Clinical Trials
7 trialsNCT03404193 2026-03-10
Venetoclax and Decitabine in Treating Participants With Relapsed/Refractory Acute Myeloid Leukemia or Relapsed High-Risk Myelodysplastic Syndrome
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT05918055 2025-12-02
Eltanexor (KPT-8602) With Inqovi (Decitabine-Cedazuridine) in High-Risk Myelodysplastic Syndromes
National Institutes of Health Clinical Center (CC)
Phase 1/2 Terminated
NCT05148234 2025-09-30
BMS-986253 in Myelodysplastic Syndromes
National Institutes of Health Clinical Center (CC)
Phase 1/2 Terminated
NCT03593915 2023-11-09
A Phase 1b/2 Study of Alvocidib Plus Decitabine or Azacitidine in Patients With MDS
Sumitomo Pharma America, Inc.
Phase 1/2 Terminated
NCT03113071 2021-03-16
Safety and Activity of Digoxin With Decitabine in Adult AML and MDS
Fox Chase Cancer Center
Phase 1/2 Terminated
NCT02469415 2018-10-16
Pacritinib for Patients With Lower-Risk Myelodysplastic Syndromes (MDS)
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT00113321 2012-08-07
Low-Dose Decitabine in Myelodysplastic Syndrome Post Azacytidine Failure
M.D. Anderson Cancer Center
Phase 2 Terminated